New Insights Into the Pathogenesis of Renal Calculi

Urologic Clinics of North America

Volumn 40, Issue 1, 2013, Pages 1-12

  Bagga, Herman Singh ^a   Chi, Thomas ^a   Miller, Joe ^a   Stoller, Marshall L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcium; Etiology; Genitourinary system; Review; Urinary calculi

Indexed keywords

CALCIUM; CARBONIC ACID; HYDROXYAPATITE; NANOPARTICLE; STRONTIUM;

AGXT GENE; ATHEROSCLEROSIS; BODY MASS; CALCIUM ABSORPTION; CALCIUM INTAKE; CALCIUM SENSING RECEPTOR GENE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CLDN14 GENE; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; EXPERIMENTAL MODEL; GENE; GENETIC LINKAGE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY CALCIFICATION; KIDNEY DISEASE; METABOLIC SYNDROME X; MOLECULAR PATHOLOGY; NEPHROLITHIASIS; NONHUMAN; OBESITY; OSTEOPONTIN GENE; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RANDALL PLAQUE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SLC3A1 GENE; VITAMIN D RECEPTOR GENE;

CALCIUM OXALATE; DISEASE PROGRESSION; HUMANS; KIDNEY CALCULI;

EID: 84870193124     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2012.09.006     Document Type: Review

References (100)

1. Eknoyan G. History of urolithiasis. Clin Rev Bone Miner Metabol 2004, 2:177-185.
2. Ramello A., Vitale C., Marangella M. Epidemiology of nephrolithiasis. J Nephrol 2000, 13(Suppl 3):S45-S50.
3. Stamatelou K.K., Francis M.E., Jones C.A., et al. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003, 63:1817-1823.
4. Uribarri J., Oh M.S., Carroll H.J. The first kidney stone. Ann Intern Med 1989, 111:1006-1009.
5. Stoller M.L., Meng M.V. Urinary stone disease 2007, Humana Press, Totowa (NJ).
6. Finlayson B., Reid F. The expectation of free and fixed particles in urinary stone disease. Invest Urol 1978, 15:442-448.
7. Kok D.J., Khan S.R. Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 1994, 46:847-854.
8. Evan A.P., Unwin R.J., Williams J.C. Renal stone disease: a commentary on the nature and significance of Randall's plaque. Nephron Physiol 2011, 119:p49-p53.
9. Coe F.L., Evan A.P., Lingeman J.E., et al. Plaque and deposits in nine human stone diseases. Urol Res 2010, 38:239-247.
10. Randall A. The origin and growth of renal calculi. Ann Surg 1937, 105:1009-1027.
11. Randall A. Papillary pathology as a precursor of primary renal calculus. J Urol 1940, 44:580.
12. Miller N.L., Gillen D.L., Williams J.C., et al. A formal test of the hypothesis that idiopathic calcium oxalate stones grow on Randall's plaque. BJU Int 2009, 103:966-971.
13. Miller N.L., Williams J.C., Evan A.P., et al. In idiopathic calcium oxalate stone-formers, unattached stones show evidence of having originated as attached stones on Randall's plaque. BJU Int 2010, 105:242-245.
14. Evan A.P., Lingeman J.E., Coe F.L., et al. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 2003, 111:607-616.
15. Evan A.P., Coe F.L., Rittling S.R., et al. Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization. Kidney Int 2005, 68:145-154.
16. Evan A.P., Bledsoe S., Worcester E.M., et al. Renal inter-α-trypsin inhibitor heavy chain 3 increases in calcium oxalate stone-forming patients. Kidney Int 2007, 72(12):1503-1511.
17. Stoller M.L., Low R.K., Shami G.S., et al. High resolution radiography of cadaveric kidneys: unraveling the mystery of Randall's plaque formation. J Urol 1996, 156:1263-1266.
18. Olgun A., Akman S., Erbil M.K. The role of RBC destruction in vascular regions with high turbulence on atherosclerosis. Med Hypotheses 2004, 63:283-284.
19. Kwon M.S., Lim S.W., Kwon H.M. Hypertonic stress in the kidney: a necessary evil. Physiology (Bethesda) 2009, 24:186-191.
20. O'Connor P.M. Renal oxygen delivery: matching delivery to metabolic demand. Clin Exp Pharmacol Physiol 2006, 33:961-967.
21. Stoller M.L., Meng M.V., Abrahams H.M., et al. The primary stone event: a new hypothesis involving a vascular etiology. J Urol 2004, 171:1920-1924.
22. Shekarriz B., Lu H.F., Stoller M.L. Correlation of unilateral urolithiasis with sleep posture. J Urol 2001, 165:1085-1087.
23. Rubenstein J.N., Stackhouse G.B., Stoller M.L. Effect of body position on renal parenchyma perfusion as measured by nuclear scintigraphy. Urology 2007, 70:227-229.
24. Rule A.D., Roger V.L., Melton L.J., et al. Kidney stones associate with increased risk for myocardial infarction. J Am Soc Nephrol 2010, 21:1641-1644.
25. Eisner B.H., Cooperberg M.R., Kahn A.J., et al. Nephrolithiasis and the risk of heart disease in older women. J Urol 2009, 181:517-518.
26. Reiner A.P., Kahn A., Eisner B.H., et al. Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study. J Urol 2011, 185:920-925.
27. Cappuccio F.P., Siani A., Barba G., et al. A prospective study of hypertension and the incidence of kidney stones in men. J Hypertens 1999, 17:1017-1022.
28. Borghi L., Meschi T., Guerra A., et al. Essential arterial hypertension and stone disease. Kidney Int 1999, 55:2397-2406.
29. Madore F., Stampfer M.J., Rimm E.B., et al. Nephrolithiasis and risk of hypertension. Am J Hypertens 1998, 11:46-53.
30. Madore F., Stampfer M.J., Willett W.C., et al. Nephrolithiasis and risk of hypertension in women. Am J Kidney Dis 1998, 32:802-807.
31. Strazzullo P., Nunziata V., Cirillo M. Abnormalities of calcium metabolism in essential hypertension. Clin Sci (Lond) 1983, 65(2):137-141.
32. Cappuccio F.P., Kalaitzidis R., Duneclift S., et al. Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. J Nephrol 2000, 13:169-177.
33. Losito A., Nunzi E.G., Covarelli C., et al. Increased acid excretion in kidney stone formers with essential hypertension. Nephrol Dial Transplant 2008, 24:137-141.
34. Taylor E.N., Mount D.B., Forman J.P., et al. Association of prevalent hypertension with 24-hour urinary excretion of calcium, citrate, and other factors. Am J Kidney Dis 2006, 47:780-789.
35. Coe F.L., Parks J.H., Asplin J.R. The pathogenesis and treatment of kidney stones. N Engl J Med 1992, 327(16):1141-1152.
36. Moe O.W. Kidney stones: pathophysiology and medical management. Lancet 2006, 367(9507):333-344.
37. Muldowney F.P., Freaney R., Moloney M.F. Importance of dietary sodium in the hypercalciuria syndrome. Kidney Int 1982, 22:292-296.
38. Luft F.C. Sodium intake and essential hypertension. Hypertension 1982, 4(5 Pt 2):III14-III19.
39. Wexler B.C., McMurtry J.P. Kidney and bladder calculi in spontaneously hypertensive rats. Br J Exp Pathol 1981, 62:369.
40. Taylor E.N., Stampfer M.J., Curhan G.C. Obesity, weight gain, and the risk of kidney stones. JAMA 2005, 293:455-462.
41. Del Valle E.E., Negri A.L., Spivacow F.R., et al. Metabolic diagnosis in stone formers in relation to body mass index. Urol Res 2012, 40:47-52.
42. Taylor E.N., Curhan G.C. Body size and 24-hour urine composition. Am J Kidney Dis 2006, 48:905-915.
43. Ekeruo W.O., Tan Y.H., Young M.D., et al. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. J Urol 2004, 172:159-163.
44. Powell C.R., Stoller M.L., Schwartz B.F., et al. Impact of body weight on urinary electrolytes in urinary stone formers. Urology 2000, 55:825-830.
45. Thamer C., Machann J., Stefan N., et al. High visceral fat mass and high liver fat are associated with resistance to lifestyle intervention. Obesity (Silver Spring) 2007, 15:531-538.
46. Blüher S., Markert J., Herget S., et al. Who should we target for diabetes prevention and diabetes risk reduction?. Curr Diab Rep 2012, 12:147-156.
47. Taylor E.N., Stampfer M.J., Curhan G.C. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int 2005, 68:1230-1235.
48. Chung S.D., Chen Y.K., Lin H.C. Increased risk of diabetes in patients with urinary calculi: a 5-year followup study. J Urol 2011, 186:1888-1893.
49. Daudon M., Traxer O., Conort P., et al. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol 2006, 17:2026-2033.
50. Canda A.E., Isgoren A.E. Re: Increased risk of diabetes in patients with urinary calculi: a 5-year followup study: S.-D. Chung, Y.-K. Chen and H.-C. Lin J Urol 2011; 186: 1888-1893. J Urol 2012, 187:2279-2280.
51. Abate N., Chandalia M., Cabo-Chan A.V. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004, 65(2):386-392.
52. Lemann J., Piering W.F., Lennon E.J. Possible role of carbohydrate-induced calciuria in calcium oxalate kidney-stone formation. N Engl J Med 1969, 280:232-237.
53. Eisner B.H., Porten S.P., Bechis S.K., et al. Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers. J Urol 2010, 183:2244-2248.
54. Kadlec A.O., Greco K., Fridirici Z.C., et al. Metabolic syndrome and urinary stone composition: what factors matter most?. Urology 2012, 80(4):805-810.
55. Inci M., Demirtas A., Sarli B., et al. Association between body mass index, lipid profiles, and types of urinary stones. Ren Fail 2012, 34(9):1140-1143.
56. Tsujihata M., Momohara C., Yoshioka I., et al. Atorvastatin inhibits renal crystal retention in a rat stone forming model. J Urol 2008, 180:2212-2217.
57. Tsujihata M., Yoshioka I., Tsujimura A., et al. Why does atorvastatin inhibit renal crystal retention?. Urol Res 2011, 39:379-383.
58. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
59. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005, 28:1769-1778.
60. Gami A.S., Witt B.J., Howard D.E., et al. Metabolic syndrome and risk of incident cardiovascular events and death. J Am Coll Cardiol 2007, 49:403-414.
61. West B., Luke A., Durazo-Arvizu R.A., et al. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994. Am J Kidney Dis 2008, 51:741-747.
62. Rendina D., Mossetti G., De Filippo G., et al. Association between metabolic syndrome and nephrolithiasis in an inpatient population in southern Italy: role of gender, hypertension and abdominal obesity. Nephrol Dial Transplant 2009, 24:900-906.
63. Jeong I.G., Kang T., Bang J.K., et al. Association between metabolic syndrome and the presence of kidney stones in a screened population. Am J Kidney Dis 2011, 58:383-388.
64. Pak C.Y., East D.A., Sanzenbacher L.J., et al. Gastrointestinal calcium absorption in nephrolithiasis. J Clin Endocrinol Metab 1972, 35:261-270.
65. Worcester E.M., Coe F.L. New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol 2008, 28:120-132.
66. Sorensen M.D., Eisner B.H., Stone K.L., et al. Impact of calcium intake and intestinal calcium absorption on kidney stones in older women: the study of osteoporotic fractures. J Urol 2012, 187:1287-1292.
67. Ireland P., Fordtran J.S. Effect of dietary calcium and age on jejunal calcium absorption in humans studied by intestinal perfusion. J Clin Invest 1973, 52:2672-2681.
68. Maalouf N.M., Kumar R., Pasch A., et al. Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int 2011, 79(4):393-403.
69. Lauderdale D.S., Thisted R.A., Wen M., et al. Bone mineral density and fracture among prevalent kidney stone cases in the Third National Health and Nutrition Examination Survey. J Bone Miner Res 2001, 16:1893-1898.
70. Melton L.J., Crowson C.S., Khosla S., et al. Fracture risk among patients with urolithiasis: a population-based cohort study. Kidney Int 1998, 53:459-464.
71. Garriguet D. Bone health: osteoporosis, calcium and vitamin D. Health Rep 2011, 22:7-14.
72. Dawson-Hughes B., Harris S.S., Krall E.A. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997, 337(10):670-676.
73. Tang B.M., Eslick G.D., Nowson C., et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007, 370:657-666.
74. Samachson J., Scheck J., Spencer H. Radiocalcium absorption at different times of day. Am J Clin Nutr 1966, 18:449-451.
75. Vezzoli G., Baragetti I., Zerbi S., et al. Strontium absorption and excretion in normocalciuric subjects: relation to calcium metabolism. Clin Chem 1998, 44(3):586-590.
76. Li C., Paris O., Siegel S., et al. Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment. J Bone Miner Res 2010, 25:968-975.
77. Vezzoli G., Rubinacci A., Bianchin C. Intestinal calcium absorption is associated with bone mass in stone-forming women with idiopathic hypercalciuria. Am J Kidney Dis 2003, 42(6):1177-1183.
78. Blaschko S.D., Miller J., Chi T., et al. Micro-composition of human urinary calculi using advanced imaging techniques. J Urol 2012, [Epub ahead of print].
79. Carpentier X., Bazin D., Combes C., et al. High Zn content of Randall's plaque: a μ-X-ray fluorescence investigation. J Trace Elem Med Biol 2011, 25:160-165.
80. Kajander E.O., Kuronen I., Akerman K.K., et al. Nanobacteria from blood: the smallest culturable autonomously replicating agent on Earth. Proceedings of SPIE 1997, 3111:420-428.
81. Ciftçioglu N., Björklund M., Kuorikoski K., et al. Nanobacteria: an infectious cause for kidney stone formation. Kidney Int 1999, 56:1893-1898.
82. Kutikhin A., Brusina, Yuzhalin A. The role of calcifying nanoparticles in biology and medicine. Int J Nanomedicine 2012, 7:339-350.
83. Kajander E.O., Ciftçioglu N. Nanobacteria: an alternative mechanism for pathogenic intra- and extracellular calcification and stone formation. Proc Natl Acad Sci U S A 1998, 95:8274-8279.
84. Khullar M., Sharma S.K., Singh S.K., et al. Morphological and immunological characteristics of nanobacteria from human renal stones of a north Indian population. Urol Res 2004, 32:190-195.
85. Chen L., Huang X.B., Xu Q.Q., et al. Beijing Da Xue Xue Bao 2010, 42(4):443-446. [in Chinese].
86. Puskás L.G., Tiszlavicz L., Rázga Z., et al. Detection of nanobacteria-like particles in human atherosclerotic plaques. Acta Biol Hung 2005, 56:233-245.
87. Miller V.M., Rodgers G., Charlesworth J.A., et al. Evidence of nanobacterial-like structures in calcified human arteries and cardiac valves. Am J Physiol Heart Circ Physiol 2004, 287:H1115-H1124.
88. Bratos-Pérez M.A., Sánchez P.L., García de Cruz S., et al. Association between self-replicating calcifying nanoparticles and aortic stenosis: a possible link to valve calcification. Eur Heart J 2008, 29:371-376.
89. Schwartz M.A., Lieske J.C., Kumar V., et al. Human-derived nanoparticles and vascular response to injury in rabbit carotid arteries: proof of principle. Int J Nanomedicine 2008, 3:243-248.
90. Cellini B., Oppici E., Paiardini A., et al. Molecular insights into primary hyperoxaluria type 1 pathogenesis. Front Biosci 2012, 17:621-634.
91. Eggermann T., Venghaus A., Zerres K. Cystinuria: an inborn cause of urolithiasis. Orphanet J Rare Dis 2012, 7:19.
92. Arikyants N., Sarkissian A., Hesse A., et al. Xanthinuria type I: a rare cause of urolithiasis. Pediatr Nephrol 2007, 22:310-314.
93. Vezzoli G., Terranegra A., Arcidiacono T., et al. Genetics and calcium nephrolithiasis. Kidney Int 2010, 80:587-593.
94. Sayer J.A. Renal stone disease. Nephron Physiol 2011, 118:p35-p44.
95. Thorleifsson G., Holm H., Edvardsson V., et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 2009, 41:926-930.
96. Evan A.P., Bledsoe S.B., Smith S.B., et al. Calcium oxalate crystal localization and osteopontin immunostaining in genetic hypercalciuric stone-forming rats. Kidney Int 2004, 65:154-161.
97. Chen Y.H., Liu H.P., Chen H.Y., et al. Ethylene glycol induces calcium oxalate crystal deposition in Malpighian tubules: a Drosophila model for nephrolithiasis/urolithiasis. Kidney Int 2011, 80:369-377.
98. Khan S.R. Animal models of kidney stone formation: an analysis. World J Urol 1997, 15:236-243.
99. Khan S.R. Nephrocalcinosis in animal models with and without stones. Urol Res 2010, 38:429-438.
100. Dow J.A., Romero M.F. Drosophila provides rapid modeling of renal development, function, and disease. Am J Physiol Renal Physiol 2010, 299:F1237-F1244.